|
Market Closed -
Nasdaq
16:00:00 2026-10-28 EDT
|
Pre-market 09:00:35 | |||
| 25.36 USD | +1.89% |
|
25.04 | -1.24% |
| 10-28 | Viking Therapeutics, Inc., Q3 2026 Earnings Call, Oct 28, 2026 | |
| 10-28 | Earnings Flash (VKTX) Viking Therapeutics Posts Q3 Loss -$1.55, vs. FactSet Est of -$1.06 Loss | MT |
Company Valuation: Viking Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 359.9 | 720.9 | 1,862 | 4,484 | 3,977 | 2,958 | - | - |
| Change | - | 100.31% | 158.23% | 140.89% | -11.32% | -25.61% | - | - |
| Enterprise Value (EV) 1 | 157.8 | 565.4 | 1,499 | 3,582 | 3,271 | 2,495 | 2,448 | 2,709 |
| Change | - | 258.34% | 165.21% | 138.86% | -8.68% | -23.72% | -1.9% | 10.69% |
| P/E | -6.48x | -10.4x | -20.5x | -39.8x | -11x | -5.52x | -5.94x | -7.89x |
| PBR | 1.78x | 4.97x | 5.35x | 5.1x | 6.32x | 6.73x | 5.1x | 12.4x |
| PEG | - | -0.4x | -18.45x | -3.6x | -0x | -0.1x | 0.84x | 0.3x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 15.6x |
| EV / Revenue | - | - | - | - | - | - | - | 14.3x |
| EV / EBITDA | -2.83x | - | -14.9x | -23.7x | -8.32x | -4.36x | -3.95x | -6.31x |
| EV / EBIT | -2.83x | -8.04x | -14.9x | -23.7x | -8.32x | -4.44x | -4.37x | -5.91x |
| EV / FCF | -3.32x | -11.7x | -20.4x | -40.8x | -4.69x | -5.03x | -5.47x | -5.81x |
| FCF Yield | -30.2% | -8.56% | -4.89% | -2.45% | -21.3% | -19.9% | -18.3% | -17.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.71 | -0.9 | -0.91 | -1.01 | -3.19 | -4.593 | -4.268 | -3.214 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 190 |
| EBITDA 1 | -55.68 | - | -100.8 | -150.9 | -393.3 | -572.2 | -619.9 | -429.4 |
| EBIT 1 | -55.68 | -70.36 | -100.8 | -150.9 | -393.3 | -562.3 | -559.9 | -458.8 |
| Net income 1 | -54.99 | -68.87 | -85.9 | -110 | -359.6 | -541.6 | -535.1 | -414.7 |
| Net Debt 1 | -202.1 | -155.5 | -362.1 | -902.6 | -705.7 | -463.4 | -510.8 | -249.3 |
| Reference price 2 | 4.60 | 9.40 | 18.61 | 40.24 | 35.18 | 25.36 | 25.36 | 25.36 |
| Nbr of stocks (in thousands) | 78,235 | 76,688 | 100,029 | 111,436 | 113,036 | 116,653 | - | - |
| Announcement Date | 2/9/22 | 2/8/23 | 2/7/24 | 2/5/25 | 2/11/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.52x | - | -4.36x | - | 2.96B | |
| 16.92x | 6.39x | 12.26x | 1.77% | 64.14B | |
| 30.57x | 8.11x | 26.59x | 0.05% | 55.53B | |
| 36.68x | 6.52x | 19.45x | 0.88% | 53.03B | |
| 35.39x | 3.41x | 14.74x | -.--% | 45.99B | |
| 49.25x | 5.68x | 31.09x | -.--% | 42.45B | |
| -19.59x | 189.6x | -20.86x | -.--% | 40.45B | |
| 31.7x | 8.06x | 20.96x | 0.41% | 32.25B | |
| 47.12x | 8.37x | 28.08x | -.--% | 34.47B | |
| 27.96x | 5.9x | 15.29x | -.--% | 24.23B | |
| Average | 25.05x | 26.89x | 14.32x | 0.34% | 39.55B | |
| Weighted average by Cap. | 27.71x | 25.38x | 16.31x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- VKTX Stock
- Valuation Viking Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
